Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 262

1.

Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic.

Carvajal-Hausdorf DE, Schalper KA, Neumeister VM, Rimm DL.

Lab Invest. 2014 Dec 15. doi: 10.1038/labinvest.2014.157. [Epub ahead of print]

PMID:
25502176
[PubMed - as supplied by publisher]
2.

Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.

Christofer Juhlin C, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, Nelson-Williams C, Bäckdahl M, Suttorp AC, Haase M, Choi M, Schlessinger J, Rimm DL, Höög A, Prasad ML, Korah R, Larsson C, Lifton RP, Carling T.

J Clin Endocrinol Metab. 2014 Dec 9:jc20143282. [Epub ahead of print]

PMID:
25490274
[PubMed - as supplied by publisher]
3.

Quantitative assessment of miR34a as an independent prognostic marker in breast cancer.

Agarwal S, Hanna J, Sherman ME, Figueroa J, Rimm DL.

Br J Cancer. 2014 Dec 4. doi: 10.1038/bjc.2014.573. [Epub ahead of print]

PMID:
25474246
[PubMed - as supplied by publisher]
4.

Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time.

Vassilakopoulou M, Parisi F, Siddiqui S, England AM, Zarella ER, Anagnostou V, Kluger Y, Hicks DG, Rimm DL, Neumeister VM.

Lab Invest. 2014 Nov 24. doi: 10.1038/labinvest.2014.139. [Epub ahead of print]

PMID:
25418580
[PubMed - as supplied by publisher]
5.

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM.

Clin Cancer Res. 2014 Oct 14. pii: clincanres.0861.2014. [Epub ahead of print]

PMID:
25316811
[PubMed - as supplied by publisher]
6.

Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer.

Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V.

Clin Cancer Res. 2014 Dec 1;20(23):5995-6005. doi: 10.1158/1078-0432.CCR-14-1622. Epub 2014 Sep 25.

PMID:
25255793
[PubMed - in process]
7.

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S.

Ann Oncol. 2014 Sep 11. pii: mdu450. [Epub ahead of print] Review.

PMID:
25214542
[PubMed - as supplied by publisher]
8.

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.

Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA.

Br J Cancer. 2014 Sep 9;111(6):1065-71. doi: 10.1038/bjc.2014.442. Epub 2014 Aug 12.

PMID:
25117817
[PubMed - indexed for MEDLINE]
9.

Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.

Shipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, Huang YE, Chang H, Rimm DL, Berman DM, Nifong TP, Blume-Jensen P.

Proteome Sci. 2014 Jul 12;12:40. doi: 10.1186/1477-5956-12-40. eCollection 2014.

PMID:
25075204
[PubMed]
Free PMC Article
10.

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.

Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM, Blume-Jensen P.

Br J Cancer. 2014 Sep 9;111(6):1201-12. doi: 10.1038/bjc.2014.396. Epub 2014 Jul 17.

PMID:
25032733
[PubMed - indexed for MEDLINE]
11.

ERβ splice variant expression in four large cohorts of human breast cancer patient tumors.

Wimberly H, Han G, Pinnaduwage D, Murphy LC, Yang XR, Andrulis IL, Sherman M, Figueroa J, Rimm DL.

Breast Cancer Res Treat. 2014 Aug;146(3):657-67. doi: 10.1007/s10549-014-3050-3. Epub 2014 Jul 10.

PMID:
25007965
[PubMed - in process]
12.

In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.

Vassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, Psyrri A.

PLoS One. 2014 Jun 26;9(6):e99131. doi: 10.1371/journal.pone.0099131. eCollection 2014.

PMID:
24968015
[PubMed - in process]
Free PMC Article
13.

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.

Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL.

BMC Cancer. 2014 May 8;14:326. doi: 10.1186/1471-2407-14-326.

PMID:
24885187
[PubMed - in process]
Free PMC Article
14.

Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.

Wilson MA, Zhao F, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, Kluger HM, Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL.

Clin Cancer Res. 2014 Jun 15;20(12):3328-37. doi: 10.1158/1078-0432.CCR-14-0093. Epub 2014 Apr 8.

PMID:
24714776
[PubMed - in process]
15.

Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.

Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA.

Clin Cancer Res. 2014 Jun 1;20(11):3023-32. doi: 10.1158/1078-0432.CCR-14-0113. Epub 2014 Apr 3.

PMID:
24700741
[PubMed - in process]
16.

Next-gen immunohistochemistry.

Rimm DL.

Nat Methods. 2014 Apr;11(4):381-3. doi: 10.1038/nmeth.2896. No abstract available.

PMID:
24681723
[PubMed - indexed for MEDLINE]
17.

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.

Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL.

Clin Cancer Res. 2014 May 15;20(10):2773-82. doi: 10.1158/1078-0432.CCR-13-2702. Epub 2014 Mar 19.

PMID:
24647569
[PubMed - in process]
18.

A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue.

Neumeister VM, Parisi F, England AM, Siddiqui S, Anagnostou V, Zarrella E, Vassilakopolou M, Bai Y, Saylor S, Sapino A, Kluger Y, Hicks DG, Bussolati G, Kwei S, Rimm DL.

Lab Invest. 2014 Apr;94(4):467-74. doi: 10.1038/labinvest.2014.7. Epub 2014 Feb 17.

PMID:
24535259
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancer.

How J, Brown JR, Saylor S, Rimm DL.

Histochem Cell Biol. 2014 Aug;142(2):195-204. doi: 10.1007/s00418-014-1181-6. Epub 2014 Jan 16.

PMID:
24429833
[PubMed - in process]
20.

Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method.

Bai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm DL, Stern DF.

PLoS One. 2013 Nov 21;8(11):e79901. doi: 10.1371/journal.pone.0079901. eCollection 2013.

PMID:
24278211
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk